Skip to content
Erasca, Inc. logo

Erasca, Inc. Alternatives & Competitors

12 companies similar to Erasca, Inc. — Our mission at Erasca is embedded in our name: To erase cancer.

Companies similar to Erasca, Inc.

Odyssey Thera logo — alternative to Erasca, Inc.

Odyssey Thera

Pioneering cellular pharmacology to discover groundbreaking cancer therapies.

Adastra Pharmaceuticals logo — alternative to Erasca, Inc.

Adastra Pharmaceuticals

Adastra is committed to transforming cancer care.

Day One Biopharmaceuticals logo — alternative to Erasca, Inc.

Day One Biopharmaceuticals

Cancer drug development comes of age.

Nexo Therapeutics logo — alternative to Erasca, Inc.

Nexo Therapeutics

We’re driven to translate the most compelling and still undrugged targets in human biolog...

Rival Readout

Competing with Erasca, Inc.? We do this properly.

10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.

Book a 7-day Readout
GenFleet Therapeutics logo — alternative to Erasca, Inc.

GenFleet Therapeutics

Innovation, in Expedition

AVEO Oncology logo — alternative to Erasca, Inc.

AVEO Oncology

Committed to delivering medicines that provide a better life for patients with cancer.

Sierra Oncology logo — alternative to Erasca, Inc.

Sierra Oncology

We are on a mission to deliver transformative therapies that treat rare forms of cancer.

Adlai Nortye logo — alternative to Erasca, Inc.

Adlai Nortye

Pioneering the future of oncology with innovative drug development across the globe.

Scorpion Therapeutics logo — alternative to Erasca, Inc.

Scorpion Therapeutics

Pioneering the Next Generation of Precision Oncology

Helioson logo — alternative to Erasca, Inc.

Helioson

A biopharmaceutical pioneer dedicated to creating groundbreaking therapies for cancer.

OncXerna Therapeutics  logo — alternative to Erasca, Inc.

OncXerna Therapeutics

Advancing a new paradigm of precision oncology with a RNA-based approach to match patients...

VRise Therapeutics, Inc. logo — alternative to Erasca, Inc.

VRise Therapeutics, Inc.

A Precision Oncology Company

About Erasca, Inc.

Erasca, a biotechnology and pharmaceutical company founded in 2018, is on a mission to "erase cancer." The company's commitment to addressing oncology's toughest challenges is fueled by recent scientific breakthroughs and advancements in targeting various biological drivers of cancer. Erasca has strategically built a f...

Business keywords

Oncology, Precision Medicine, Drug Development, Cancer Research, Biopharmaceutical, Precision Oncology, Biology, Collaborations, Pipeline Expansion, Scientific Discoveries, Precision Oncology Options, Academic Partnerships, San Diego, California

Frequently Asked Questions

Companies similar to Erasca, Inc. include Odyssey Thera, Adastra Pharmaceuticals, Day One Biopharmaceuticals, Nexo Therapeutics, GenFleet Therapeutics. They work in Biotechnology and Pharmaceutical and share Erasca, Inc.'s focus on precision medicine, drug development and oncology.
Bounce Watch lists 12 companies that share Erasca, Inc.'s industries and are closest to it in business tags, services, target customers, business model and size.
Erasca, a biotechnology and pharmaceutical company founded in 2018, is on a mission to "erase cancer." The company's commitment to addressing oncology's toughest challenges is fueled by recent scientific breakthroughs and advancements in targeting various biological drivers of cancer. Erasca has strategically built a f...

From the desk

Mapping a market? Start with a Rival Readout.

In 7 business days we read 10 rivals around Erasca, Inc.: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.

Compiled from the BounceWatch company index. We last looked at Erasca, Inc. on 9 Jun 2026. The 12 companies listed here were last checked between 11 Sep 2024 and 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout